---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007821"
form_type: "8-K"
ticker: "INTI"
cik: "0001042418"
company_name: "Inhibitor Therapeutics, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:37:45.655290+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inhibitor Therapeutics enters $3M private placement; sells 12M shares and warrants

## Summary
- Company to sell 12,000,000 shares of common stock at $0.25/share to an institutional investor, raising $3M.
- Investor receives warrants to purchase up to 7,000,000 shares at $0.35/share, exercisable for 3 years.
- Proceeds from the private placement will be used for working capital and general corporate purposes.
- Shares and warrant shares are subject to a 9-month lock-up agreement that restricts resale.
- Closing has not yet occurred; expected within a reasonable time after the filing date.

## SEC filing metadata
- accession: 0001493152-26-007821
- form_type: 8-K
- ticker: INTI
- cik: 0001042418
- company_name: Inhibitor Therapeutics, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1042418/000149315226007821/0001493152-26-007821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042418/000149315226007821/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007821
- JSON: https://secwatch.observer/filing/0001493152-26-007821.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007821.txt

## Key facts
- Material Agreements
  Inhibitor Therapeutics, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $3,000,000 (effective 2026-02-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional investor
  - Value: $3,000,000
  - Effective: 2026-02-19
  source text: On February 19, 2026, Inhibitor Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ SPA ”) with an institutional investor (the “ Investor ”), for certain financing (the “Financing”), pursuant to which the Company has agreed to sell to the Investor 12,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”) and to issue to the Investor a Common Stock Purchase Warrant to purchase up to 7,000,000 shares of Common Stock (the “Warrant”), in consideration for the Investor’s investment of $3,000,000 therefor ($0.25 per share of Common Stock and accompanying Warrant).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000149315226007821/0001493152-26-007821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.